BAROnova Transpyloric Shuttle (TPS) for Treating Obesity

May 1, 2017 | Technology Forecasts


Note: The following ratings and comments reflect the opinions and consensus of an expert panel convened by ECRI Institute to review information on this topic.

Anticipated Utilization: 1(Expected to be used by <20% of eligible patients)

The Transpyloric Shuttle® (TPS®, BAROnova, Inc., Goleta, CA, USA), if approved for marketing, will enter a saturated antiobesity treatment market, given the pharmacologic and minimally invasive options already available. We expect utilization to be limited to <1% of the eligible population, especially given the low uptake of other pharmacologic and minimally invasive antiobesity treatments, and because insurance coverage is not likely. Uncertainty of TPS's long-term effects on sustained weight loss could also temper utilization.

Estimated Adoption Status: 1(Early...

Access Full Content

Contact us today at 610.825.6000.

Related Tags